Gardiquimod (diTFA)

Gardiquimod diTFA is an imidazoline TLR7/8 agonist. Gardiquimod diTFA inhibits HIV-1 infection of macrophages and activated peripheral blood mononuclear cells (PBMCs) . Gardiquimod diTFA specifically activates TLR7 at concentrations below 10 μM.

Product Specifications

CAS Number

[1159840-61-5]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Toll-like Receptor (TLR)

Type

Reference compound

Related Pathways

Immunology/Inflammation

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/Gardiquimod_trifluoroacetate.html

Purity

99.0

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : 25 mg/mL (ultrasonic)

Smiles

OC(C)(C)CN1C(CNCC)=NC2=C1C3=CC=CC=C3N=C2N.FC(C(O)=O)(F)F.FC(C(O)=O)(F)F

Molecular Formula

C21H25F6N5O5

Molecular Weight

541.44

Precautions

H302, H315, H319, H335

References & Citations

[1]Buitendijk M, et al. Gardiquimod: a Toll-like receptor-7 agonist that inhibits HIV type 1 infection of human macrophages and activated T cells. AIDS Res Hum Retroviruses. 2013 Jun;29 (6) :907-18.|[2]Ma F, et al. The TLR7 agonists imiquimod and gardiquimod improve DC-based immunotherapy for melanoma in mice. Cell Mol Immunol. 2010 Sep;7 (5) :381-8.|[3]Zhou Z, et al. TLR7/8 agonists promote NK-DC cross-talk to enhance NK cell anti-tumor effects in hepatocellular carcinoma. Cancer Lett. 2015 Dec 28;369 (2) :298-306.